Back to Search
CARMELITA PISANO, M.D.
M.D.
Anesthesiology Physician
NPI: 1689862054IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anesthesiology PhysicianPrimary
Anesthesiology
Code: 207L00000X
230396(MA)
CMS Specialties
PrimaryANESTHESIOLOGY
Education
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
Class of 2004
Research & Publications (20)
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
PMID 18445521·Eur J Cancer·2008
7-preclinical
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
PMID 18645015·Mol Cancer Ther·2008
7-preclinical
Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models.
PMID 17698835·Ann Oncol·2007
7-preclinical
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.
PMID 15496501·Glycobiology·2005
7-preclinical
Cellular and pharmacological bases of the antitumor activity of a novel adamantyl retinoid, ST1926.
PMID 15688616·J Chemother·2004
4-observational
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
PMID 14654561·Clin Cancer Res·2003
7-preclinical
Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells.
PMID 12393712·Blood·2002
8-other
Changes in microtubule organization after exposure to a benzimidazole derivative in Chinese hamster cells.
PMID 11077003·Mutagenesis·2000
7-preclinical
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
PMID 19179095·Crit Rev Oncol Hematol·2009
8-other
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
PMID 19266200·Cancer Chemother Pharmacol·2009
3-trial
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
PMID 19285395·Bioorg Med Chem Lett·2009
4-observational
Fine-needle cytology of metastatic endometrioid neoplasms: experience with eight cases.
PMID 19191293·Diagn Cytopathol·2009
5-case
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.
PMID 19276160·Mol Cancer Ther·2009
4-observational
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
PMID 19039248·Oncology·2009
3-trial
Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
PMID 19359173·Bioorg Med Chem Lett·2009
8-other
Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
PMID 19084294·Eur J Med Chem·2009
8-other
Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.
PMID 19309124·Bioconjug Chem·2009
8-other
Triplex formation on DNA targets: how to choose the oligonucleotide.
PMID 18954091·Biochemistry·2008
8-other
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity.
PMID 18790775·Mol Cancer Ther·2008
7-preclinical
Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
PMID 18783207·J Med Chem·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 75 FRANCIS ST
BOSTON, MA 02115 - Phone
- (617) 732-5500
Quick Facts
- NPI
- 1689862054
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 22
- Publications
- 20
Are you this provider?
Claim Your Profile